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A large body of evidence exists on the role of dopamine in reinforcement learning. Less is known about how dopamine shapes the
relative impact of positive and negative outcomes to guide value-based choices. We combined administration of the dopamine D2
receptor antagonist amisulpride with functional magnetic resonance imaging in healthy human volunteers. Amisulpride did not
affect initial reinforcement learning. However, in a later transfer phase that involved novel choice situations requiring decisions
between two symbols based on their previously learned values, amisulpride improved participants’ ability to select the better of
two highly rewarding options, while it had no effect on choices between two very poor options. During the learning phase, activity
in the striatum encoded a reward prediction error. In the transfer phase, in the absence of any outcome, ventromedial prefrontal
cortex (vmPFC) continually tracked the learned value of the available options on each trial. Both striatal prediction error coding
and tracking of learned value in the vmPFC were predictive of subjects’ choice performance in the transfer phase, and both were
enhanced under amisulpride. These findings show that dopamine-dependentmechanisms enhance reinforcement learning signals
in the striatum and sharpen representations of associative values in prefrontal cortex that are used to guide reinforcement-based
decisions.
Introduction
The ability to learn about the relative value of various available
options and to make choices between alternatives on the basis of
these associative values is a hallmark of adaptive, goal-directed
behavior. The neuromodulator dopamine, particularly in the
striatum, has long been known to be crucial for reinforcement
learning (Wise, 2004). Striatal dopamine is important for learn-
ing to both approach rewarding outcomes and avoid aversive
outcomes (Salamone, 1994; Salamone and Correa, 2002). How-
ever, it is less clear how learning about the values of stimuli or
actions translates into later choice behavior in new situations that
require decisions on the basis of these learned values. A compu-
tational model of basal ganglia dopamine function suggests that
dopamine in the striatum facilitates learning from positive out-
comes through its action on D1 receptors on striatonigral neu-
rons, whereas learning from negative outcomes is assumed to be
mediated by decreased dopamine transmission via D2 receptors
on striatopallidal neurons (Frank, 2005). This model has been
supported by data from patients suffering from Parkinson’s dis-
ease (PD), which results from a profound depletion of dopamine
in the dorsal striatum (Frank et al., 2004). Similarly, individuals
with a genetically driven reduction in D2 receptor density were
impaired at learning from negative but not positive outcomes
(Klein et al., 2007). Notably, a central aspect of the tasks used in
these studies is that they involve a reinforcement learning phase,
where subjects learn the values of various stimuli, and a later
transfer phase. In this transfer phase, subjects’ decisions are
guided by the associative values previously acquired. It is not clear
whether the observed results represent solely an effect of dopa-
mine on reinforcement learning or choice behavior. Thus, it
could be argued that dopaminergic genes or PD-induced dopa-
mine depletion acted on value-based choice behavior (i.e., behav-
ior in the transfer phase), either instead of or in addition to action
on reinforcement learning. The absence of behavioral differences
during the initial learning phase in these studies is consistent with
this interpretation (Frank et al., 2004; Klein et al., 2007). The
ventromedial prefrontal cortex (vmPFC) is a key structure for
value-based decisions. It has been implicated in encoding repre-
sentations of expected value (O’Doherty, 2004; Blair et al., 2006;
Padoa-Schioppa and Assad, 2006; Gla¨scher et al., 2009), and its
integrity is crucial to human value-based choices (Bechara et al.,
1994, 2000).While there is an abundance of literature on the role
of dopamine in reinforcement learning, little is known about the
role of this neuromodulator in signaling learned values in the
vmPFC and in value-based choices.
Our aim was as follows: (1) to investigate for the first time
the role of dopamine D2 receptors in reinforcement learning
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signals in this kind of task with functional magnetic resonance
imaging (fMRI) under a direct pharmacological challenge; and
(2) to test whether dopaminergicmodulation, in addition to pos-
sibly affecting reinforcement learning, also impacts representa-
tions of learned value in the vmPFC.
Materials andMethods
Subjects. Eighteen volunteers participated in the fMRI study. We in-
cluded only male subjects to avoid menstrual cycle-dependent interac-
tions between the dopaminergic system and gonadal steroids (Becker et
al., 1982; Becker and Cha, 1989; Creutz and Kritzer, 2004; Dreher et al.,
2007). One participant dropped out for reasons unrelated to the study,
and another was excluded because of excessive head motion. The result-
ing 16 subjects (age: 26.13 0.85 years, body weight: mean 78.75 1.85
kg, mean SEM) were included in further data analysis. All participants
gave written informed consent to the procedure, which had been ap-
proved by the local ethics committee of the Medical Faculty of the Uni-
versity of Cologne (Cologne, Germany).
Drug administration. Each subject received once, in a double-blind
fashion, a pill that contained either placebo, the D2-selective antagonist
amisulpride (200 mg), or the D2 receptor agonist pramipexole (0.5 mg)
on separate occasions, which were separated by at least 1 week to assure
completewashout of the drug before the nextmeasurement. The order of
treatments was balanced across subjects. Subjects were informed about
the drugs’ pharmacological properties, their general clinical use, and
possible adverse effects before inclusion in the study. Exclusion criteria
included history of neurological or psychiatric illness, drug abuse, and
use of psychoactive drugs or medication in the 2 weeks before the exper-
iment. In addition, subjects were instructed to abstain from alcohol and
any other drugs of abuse during the entire course of the study. Because
pramipexole induced a number of nonspecific effects, among them a sup-
pressionof visually evoked activity in the checkerboard control task, thedata
from this condition were not further analyzed and are not reported here.
Study procedure. After informed consent was obtained, subjects first
completed a full version of the reinforcement learning and choice task (as
described below in the next section) without
fMRI scanning. This was done to avoid initial
learning effects in the first fMRI session. For
the twomeasurements with fMRI andmedica-
tion (or placebo), the procedurewas as follows.
After arrival, volunteers completed a visual an-
alog scale (Bond and Lader, 1974) to assess
subjective effects of the drugs, such as sedation.
Thereafter, measurements of heart rate and
blood pressure were obtained. Next, a first ve-
nous blood sample was obtained for determi-
nation of baseline (undrugged) levels of
prolactin. This was followed by administration
of drug or placebo. fMRI measurements began
about 150 min after drug administration,
which is approximately the time at which
amisulpride reaches peak blood levels. Ap-
proximately 15 min before the start of fMRI
measurements (immediately before position-
ing in the scanner), subjects’ heart rate and
blood pressure were again controlled, they
filled out the visual analog scales a second time,
and a second blood sample for determination
of prolactin levels under drug or placebo was
collected. In the scanner, subjects first com-
pleted the learning and choice task, which
lasted slightly less than 40 min. This was fol-
lowed by a flashing checkerboard task that
served to investigate nonspecific effects of the
drugs on hemodynamic activity. Because neu-
ronal dopamine receptors are sparse in the oc-
cipital cortex (Lidow et al., 1991; Hall et al.,
1996), drug effects on activity induced by vi-
sual stimulation are likely not mediated by
neuronal dopamine receptors. Thereafter, field maps were acquired for
later B0 unwarping of the functional images. This was followed by a 60
trial forced choice reaction time task (still in the scanner, but without
MRI measurements) to control for possible drug-induced psychomotor
retardation. Thereafter, participants left the scanner room and com-
pleted the trail-making task (versions A and B). This was done to assess
nonspecific drug effects on attention. Finally, subjects’ heart rate and
blood pressure were again measured and, if they felt well, subjects were
paid out and released. Rating scores from the analog scales are shown in
Table S1, results from the trail-making task are in Table S2, and heart rate
and blood pressure results are in Table S3 (each available at www.
jneurosci.org as supplemental material). Change in prolactin levels are
shown in Table S4. After the final session, participants were debriefed
about the purpose of the study and about the order in which they had
received drug or placebo, respectively.
Reinforcement learning and choice task. The task that we used was
adapted from the probabilistic selection task developed by Frank et al.
(2004) (Fig. 1). The reinforcement learning and choice task consisted of
two phases: an initial reinforcement learning phase and a subsequent
transfer phase. During the learning phase, subjects were presented with
three pairs of symbols that were probabilistically associated with reward.
In each pair, one symbol was always “better” (i.e., higher reward proba-
bility) than the other, but the differences in reward probability were
unequal across the three pairs: The probabilities for pairs AB, CD, and EF
were 80/20, 70/30, and 60/40%, respectively. Symbol pairs were pre-
sented in random order 120 times each, thus totaling 360 trials. For each
pair of symbols, the side (left/right) of presentation on the screen was
pseudorandomized such that each symbol appeared on each side in half
of the trials. New sets of six symbols were used on each session.Mean trial
duration was 4 s. Additionally, 36 null events of the same duration were
randomly interspersed. Subjects had to indicate their choice with the
index finger of the left or right hand.On each trial, a central fixation cross
(duration randomly jittered between 0, 500, 1000, and 1500 ms) was
displayed. This was followed by presentation of the symbols, which re-
mained on screen until the subject responded or 1700 ms elapsed. A
Figure1. Sequence of stimulus eventswithin a trial of the reinforcement learning and choice task.A, Following selection of one
of the two stimuli, the choice was visualized to the subject by a white frame (presented for 300 ms) around the corresponding
symbol. This was immediately followed by positive or negative feedback, according to the task schedule. B, In the subsequent
choice phase, symbols were rearranged to yield 12 novel combinations of symbols. In addition, the three pairs from the learning
phase were also presented. Trials were identical to those from the learning phase, with the exception that no outcome was
presented. Of particular interest in this phasewere so-calledwin–win trials (highlighted in blue) and lose–lose trials (highlighted
in red) in which two symbols associated with a very high or very low probability of reinforcement, respectively, were combined.
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subject’s choice was confirmed by a white frame around the correspond-
ing symbol, which remained on screen (together with the symbols) for
300 ms. Immediately thereafter, the outcome (a smiling face indicating a
reward of 0.01 Euro or a frowning face for no reward) was revealed. The
cumulative reward was paid out at the end of the experiment. Trials in
the transfer phase were identical to those in the learning phase, with the
exception that, to prevent new learning, no outcome was revealed. Sub-
jects were however informed that they would also receive 0.01 Euro for
each “correct” choice made in this phase. In the transfer phase, subjects
were confronted with the three symbol combinations from the learning
phase in addition to all 12 possible novel symbol combinations. Each of
these 15 symbol combinations was shown 12 times. Additionally, 18 null
events of the same duration were randomly interspersed. We analyzed
the number of correct choices on each symbol pair over the entire course
of the learning phase and in bins of 20 trials for each pair. In the transfer
phase, we computed the percentage of correct choices of the better sym-
bol in difficult-to-decide trials: win–win trials (AC, AE, and CE) and
lose–lose trials (BD, BF, and DF). These should reveal whether partici-
pants had learned more detailed value representations from positive or
negative outcomes. Furthermore, we calculated the percentage of correct
choices in choose A trials (AC, AD, AE, and AF) and avoid B trials (BC,
BD, BE, and BF).
Forced choice reaction time task. This task was administered to test
whether the drug caused psychomotor retardation. A fixation cross was
presented centrally. On each of the 60 trials, a symbolic square button
was presented horizontally to the left or right (30 left, 30 right in random-
ized order) of the fixation cross. Trials were separated by 1500 ms be-
tween the response and the onset of next stimulus. Subjects’ were
instructed to respond with the corresponding index finger as fast and as
accurate as they could. Reaction times on this task were not affected by
amisulpride relative to the drug-free condition (Table S5, available at
www.jneurosci.org as supplemental material).
Trail-making task. This pencil–paper task requires subjects to connect,
in ascending order, numbers with straight lines (part A) or connect let-
ters and numbers in ascending order, alternating between letters and
numbers (part B). This served as a test for attention and visuomotor
speed. No differences were observed between the treatment conditions
(Table S2).
Checkerboard stimulation. After an initial fixation of 10 s [equivalent to
five volumes, repetition time (TR): 2 s], a checkerboard flashing at a
frequency of 8 Hz was presented for 20 s. This was followed by a 20 s rest
block during which only the dark gray central fixation cross was pre-
sented. Rest and stimulation periods alternated until six blocks of each
were completed. The checkerboard task served to assess potential non-
specific drug effects on local blood flow. Because the occipital cortex is
virtually devoid of dopamine receptors, any drug-induced changes in
activity evoked by the visual stimulation reflect effects of dopamine on
non-neuronal dopamine receptors. We found no differences between
amisulpride and placebo in visually evoked activity. As an additional
control measure, we also contrasted right- and left-handed responses
during the learning phase of the reinforcement learning and choice task.
Again, no differences in motor-related activity were found between drug
and placebo.
Additional behavioral analyses. We analyzed whether further behav-
ioral parameters were influenced by amisulpride.Win–stay behavior was
defined as choosing the same symbol again on the next trial after having
received a reward the last time this symbol was chosen. Accordingly,
lose–shift behavior was defined as choice of the alternative symbol on the
next trial after having received no reward the last time this symbol was
chosen. Exploratory choices were defined as choices of the symbol with
the lower Q value in each pair. Furthermore, reaction times for various
trial types were analyzed. For the learning phase, reaction times for all
three pairs of symbols (AB, CD, and EF) were calculated separately. For
the transfer phase, reaction times were calculated for choose A and avoid
B trials and forwin–win and lose–lose trials These various trial typeswere
analyzed overall and separated according to correct and incorrect
choices. The results are shown in supplemental Table S5.
Reinforcement learningmodel. A standard action–value learningmodel
(Sutton and Barto, 1998; Jocham et al., 2009) was fitted to subjects’
behavior in the reinforcement learning phase. For each of the six stimuli,
A to F, the model estimates an action value,Q(A) toQ(F), on the basis of
the sequence of choices made and the outcomes experienced by the sub-
ject. These values are initialized with zero and are then updated on each
trial where the respective stimulus was chosen according to the following
rule: Qt1(A)  Qt(A)   * t. The prediction error  on trial t is the
difference between the actual and the expected outcome: t rtQt(A),
where rt is the reward on trial t, which is either one or zero. The learning
rate  scales the impact of the prediction error, i.e., the degree to which
the prediction error is used to update action values. The probability of the
model for selecting one particular stimulus from a pair, for instance A
from the AB pair, is given by the softmax rule, which is a probabilistic
choice rule: pt(A) exp(Qt(A)/)/[exp(Qt(A)/) exp(Qt(B)/)]. The
parameter  reflects the subject’s bias toward either exploratory (i.e.,
random choice of one response) or exploitatory (i.e., choice of the re-
sponse with the highest Q value) behavior. Both  and  are free model
parameters that are fit to subjects behavior such as to maximize the
model’s likelihood for the choices that were actually made by the subject.
Iterations were run across both parameters from 0.001 to 1 for  and
from 0.001 to 3 for  with a step size of 0.001. Thus,  and  can take
values ranging from 0.001 to 1 or 3, respectively. The best fitting param-
eters are those that yield the highest probability of the model for the
response that was actually made by the subject on any given trial. This is
calculated by the log likelihood estimate: LL  log(tP_Cht). P_Cht is
the probability of themodel tomake the choice that was actuallymade by
the subject on trial t. The LL was 128.61 14.08 (mean SEM) for the
placebo and 120.73 11.3 for the amisulpride condition (difference not
significant).
Acquisition and analysis of fMRI data. Data acquisition was performed
at 3 T on a Siemens Magnetom Trio equipped with a standard birdcage
head coil. Thirty slices (3 mm thickness, 0.3 mm interslice gap) were
obtained parallel to the anterior commissure–posterior commissure line
using a single-shot gradient echo-planar imaging (EPI) sequence [TR:
2000 ms; echo time (TE): 30 ms; bandwidth: 116 kHz; flip angle: 90°;
64  64 pixel matrix; field of view (FOV): 192 mm] sensitive to blood
oxygen level-dependent (BOLD) contrast. A high resolution brain image
(three-dimensional reference dataset) was recorded from each partici-
pant in a separate session using an modified driven equilibrium Fourier
transform sequence. For B0 unwarping of the EPI images, field maps
were acquired using a gradient echo sequence (TR: 1260 ms; TE: 5.20,
9.39 and 15.38ms; flip angle: 60°; 128 128 pixelmatrix, FOV: 210mm)
of the same geometry as the EPI images. Analysis of fMRI data was
performedusing tools from the FunctionalMagnetic Resonance Imaging
of the Brain Software Library (Smith et al., 2004). Functional data were
motion corrected using rigid body registration to the central volume
(Jenkinson et al., 2002). Geometric distortions in the EPI images were
corrected using the field maps and an n-dimensional phase unwrapping
algorithm (Jenkinson, 2003). Low-frequency signals were removed using
Gaussian-weighted lines 1/100Hz high-pass filter. Spatial smoothingwas
applied using a Gaussian filter with 6 mm full width at half maximum.
Slice time acquisition differences were corrected using Hanning win-
dowed sinc interpolation. EPI images were registered with the high res-
olution brain images and normalized into standard [Montreal
Neurological Institute (MNI)] space using affine registration (Jenkinson
and Smith, 2001). A general linear model was fitted into prewhitened
data space to account for local autocorrelations (Woolrich et al., 2001).
For analysis I, a general linear model was set up to investigate activity
related to rewards and punishments and activity related to the trial-by-
trial amplitude of the reward prediction error in the learning phase. To
account for the main effect of outcomes, two regressors modeling posi-
tive and negative outcomes at feedback onset were included. A third
regressor consisted of the amplitude of the (signed) reward prediction
error, also modeled at the time of the outcome.
For analyses IIa and b (transfer phase), we investigated which areas
showed higher activity during win–win compared with lose–lose trials
(a) and during choose A compared with avoid B trials (b), respectively.
The respective trial types were modeled at stimulus onset and contrasted
against each other. Trial types that fell into neither class were modeled as
events of no interest. Analyses IIIa and b investigated which areas of the
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brain covaried with the learned value of the stimuli in the transfer phase.
Using the model-derived action values at the end of the learning phase,
we constructed regressors that contained (a) for each trial the relative
value of the stimulus that was actually chosen, Vrelchosen  Vchosen 
Vunchosen, or (b) each trial’s learned value, Vstate, which is the action
values for both stimuli weighted by the model’s probability (softmax
choice probability) of choosing them.An additional regressor containing
the onsets of the symbols was included in the general linear model to
account for the main effect of stimulus presentation. Further analyses
were conducted to assess potential nonspecific drug effects on hemody-
namic activity (visually evoked activity in the checkerboard paradigm
and motor-related activity as assessed by the contrast between left hand
and right hand responses during the learning phase). All analyses were
first performed separately for both drug conditions to detect patterns of
activation. Subsequently, paired t-tests were performed to assess differ-
ences in brain activity between the two treatment conditions. Results are
reported on the whole-brain level. Unless stated differently, we used a
relatively liberal statistical threshold of p 0.001, uncorrected. For cor-
relations with behavior, parameter estimates were extracted from the
peak coordinates of these contrasts.
Results
Amisulpride effects on reinforcement learning and on choices
in the transfer phase
Subjects learned to reliably choose the better option from all
three pairs of symbols over the course of the six learning blocks
( p 0.001 for main effect of block for all
three symbol pairs; Fig. S1, available at
www.jneurosci.org as supplemental ma-
terial). Learning was generally not af-
fected by amisulpride. There was neither
an effect of drug nor a drug by block in-
teraction in any of the three symbol pairs
(all ps  0.21). Furthermore, perfor-
mance on probe trials in the transfer
phase (the original pairs from the learning
phase) was not modulated by amisulpride
(Fig. 2A). A number of other behavioral
parameters did not differ between condi-
tions (see supplemental results for addi-
tional behavioral analyses and results).
We fitted a reinforcement learning
model to subjects’ data from the learn-
ing phase. Neither the learning rate 
(placebo: 0.14869  0.02387; amisul-
pride: 0.1444  0.02013, mean  SEM) nor the temperature 
(placebo: 0.2017  0.0241; amisulpride: 0.2147  0.01485) dif-
fered between the two treatments ( p 0.65). The action values at
the endof the reinforcement learningphase showed adecreasewith
decreasing reinforcement probability (main effect of symbol:
F(5,75)  97.62, p  0.001) (Fig. 2B). Thus, the best options had
also acquired the highest action values. However, none of these
action values differed between placebo and amisulpride (no effect
of group, no symbol drug interaction, p 0.38).
In the transfer phase, amisulpride significantly improved per-
formance onwin–win trials but not on lose–lose trials. Repeated-
measures ANOVA yielded an interaction of drug  trial type
(F(1,15) 4.54, p 0.05). Post hoc paired t-test revealed that this
was due to an improvement of win–win performance under
amisulpride (p 0.012), whereas lose–lose performance was un-
changed (p  0.85) (Fig. 3). Interestingly, participants’ perfor-
mance under placebo was above chance level only in lose–lose
trials (p  0.006), but not in win–win trials (p  0.214, one
sample t-test). We also analyzed the trial classification scheme
originally used (choose A and avoid B trials) (Frank et al., 2004).
We found exactly the same pattern, namely improved choose A
performance under amisulpride (amisulpride vs placebo: p 
0.023) and no effects on avoid B performance (p  0.73, pre-
planned comparisons). As expected from the larger differences in
reward probabilities, both choose A performance and avoid B
performance were significantly above chance level regardless of
treatment (p  0.001) (supplemental Fig. S2, available at www.
jneurosci.org as supplemental material).
To rule out that the amisulpride-induced improvement in
win–win and choose A performance results from interference
with a different form of learning, namely extinction, we analyzed
the time course of choose A and win–win performance by split-
ting the transfer phase into three blocks of equal length. Subjects
in the transfer phase responded under extinction conditions, as
no immediate outcome was presented (even though subjects re-
ceived a reward for every correct choice at the end of the transfer
phase). We found no evidence of extinction: Both choose A per-
formance and win–win performance were remarkably stable
across the three blocks. There was a main effect of treatment
(F(1,15)  7.79, p  0.015) but no effect of block (F(2,30)  1.09,
p 0.35) nor a treatment block interaction (F(2,30) 0.29, p
0.75) for win–win performance. Similar results were obtained for
choose A performance.
Figure 2. A, Performance on probe trials of the transfer phase. The three symbol pairs previously presented in the learning
phase were also administered in the transfer phase, but in the absence of an outcome. This served as a measure of how well the
initial discrimination had been learned.B, Action values for the six symbols at the end of the learning phasewere estimated by the
reinforcement learning algorithm.
Figure 3. Percentage of correct choices of the better symbol on win–win (AC, AE, and CE)
and lose–lose trials (BD, BF, and DF) in the transfer phase. *p 0.05, paired t-test against
placebo. AMI, Amisulpride; PLA, placebo.
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BOLD activity in the reinforcement
learning and transfer phases
During the learning phase, rewarding out-
comes engaged the striatum, in particular
the ventral striatum (Fig. 4). In addition,
there was a small focus of activity related
to reward receipt in the vmPFCunder pla-
cebo, which was more pronounced under
amisulpride (MNI x  8, y  47, z 
11, 244 mm3, z-max  4.04, paired
t-test) (Fig. 4). Analysis of the parameter
estimates from the peak coordinate of this
difference showed that this effect was pri-
marily driven by a more pronounced sig-
nal decrease in response to negative
outcomes under amisulpride. Preplanned
comparisons showed that therewas stron-
ger signal decrease to negative outcomes
under amisulpride (p 0.044) and no ef-
fect on reward responses (p  0.75) (see
Fig. 6, left).
BOLD responses correlated with the
model-derived reward prediction error
were found in the striatum, in particular
in mid-ventral parts of the caudate nu-
cleus as well as in the bilateral lateral pre-
frontal cortex and the cingulate cortex.
Reward prediction error coding in the
striatumwas enhanced under amisulpride
(MNI x  9, y  5, z  1, 48 mm3,
z-max  3.43). Notably, reward-related
responses in the striatum and vmPFC nei-
ther correlated with performance during
the learning nor the transfer phase. In
contrast, prediction error responses in the
striatum (parameter estimates again ex-
tracted from the peak coordinate of the
difference between drug and placebo)
were predictive of later performance on
win–win trials in the transfer phase (r 
0.320, p 0.037) (see Fig. 7, left).
In the transfer phase, we first found
that the vmPFC showed higher activity
during chooseA trials than during avoid B
trials in the amisulpride, but not in the
placebo condition. Paired t-test also re-
vealed a difference between amisulpride
and placebo (MNI x  6, y  59, z  0,
1165 mm3, z-max  3.82 and MNI x
8, y 56, z10, 176 mm3, z-max
4.19, respectively) (Fig. 5A). The parame-
ter estimates from this peak coordinate (Fig. 6, right) suggest that
this was due to a nonsignificant enhancement of both the signal
increase to choose A trials and the signal decrease to avoid B trials
under amisulpride (p  0.11 and p  0.217, respectively, pre-
planned comparisons). Because the vmPFC has been implicated
in encoding the expected value of stimuli (O’Doherty, 2004;
Blair et al., 2006; Padoa-Schioppa and Assad, 2006; Gla¨scher et
al., 2009) and because no outcome is revealed, we reasoned that
the observed difference in vmPFC activity could only be due to
differences in the trials learned values.
We first found that activity in the vmPFC correlated with the
trials’ overall learned value, Vstate in the amisulpride condition
(MNI x9, y 43, z12, 59 mm3, z-max 3.36) and at a
lower threshold in the placebo condition (MNI x 8, y 61, z
19, z-max  2.31). Paired t-test confirmed that activity in the
vmPFC correlated stronger with Vstate in the amisulpride com-
paredwith the placebo condition (MNI x16, y 39, z8,
z-max 3.15) (Fig. 5B). This is consistent with the poor perfor-
mance of placebo-treated volunteers in win–win trials. In fact,
the magnitude of vmPFC activity related to Vstate predicted sub-
jects’ performance on win–win trials: Higher activity was associ-
atedwith better performance (r 0.355, p 0.023) (Fig. 7, right)
across subjects in both conditions. In addition, we found that
activity in the posterior putamen correlated with Vrelchosen (pla-
Figure 4. Signal change related to the receipt of a reward (top) and to reward prediction errors (bottom). Signal change in the
striatum and ventromedial prefrontal cortex was found in both the placebo (PLA; left) and amisulpride condition (AMI; middle).
Amisulpride increased both reward-related signal change in the ventromedial prefrontal cortex andprediction error-related signal
change in the striatum compared with placebo (right). Images are thresholded at z 3.09.
Figure 5. Signal change related to choose A versus avoid B trials (top) and to the learned value of the symbols on each trials
(bottom). Amisulpride (AMI) increased the effect of choose A versus avoid B trials (right, top) and the activity related to the
symbols’ learned value (right, bottom) in the ventromedial prefrontal cortex. Images are thresholded at z 2.3 for display
purposes. The green crosshairs are positioned at x 0, y 48 for comparisonwith the effect of amisulpride on reward processing
shown in the upper right-hand panel of Figure 4. PLA, Placebo.
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cebo: MNI x 26, y 3, z10, 232 mm3 andMNI x27,
y8, z 9, 44m3 z-max 3.71; amisulpride:MNI x 28, y
12, z 4, 1185mm3,MNI x24, y5, z7, 914mm3,
andMNI x30, y15, z 7, 861mm3, z-max 4.34) (Fig.
S3, available atwww.jneurosci.org as supplementalmaterial). Iden-
tical patterns of activation were found when we repeated the
analysis usingVchosen instead ofVrelchosen as parametric regressor.
Putaminal activity related to Vrelchosen also correlated with sub-
jects’ performance on win–win trials in both the placebo (r 
0.456, p  0.038) and amisulpride condition (r  0.578, p 
0.009).However, striatal activity related toVrelchosen did not differ
between treatment conditions.
Discussion
This study reveals that low-dose antagonism of dopamine D2
receptors can profoundly affect value-based choice behavior
without significant effects on prior reinforcement learning. In-
deed, learning to choose the more frequently rewarded of two
symbols was not influenced by the drug. In accordance with this,
model-estimated action values at the end of the learning phase
did not differ between treatment conditions. In contrast, behav-
ior during the transfer phase, where no performance feedback
was given, was markedly altered by amisulpride. Performance on
trials that required decisions between two highly reward-
associated symbols (win–win trials) was improved by amisul-
pride. No effect was found on decisions between two very low
reward-associated symbols (lose–lose trials). The same pattern
was found when we compared choose A trials (novel combina-
tions of the best symbol with all other symbols) and avoid B trials
(novel combinations of the worst symbol
with all other symbols): Again, amisul-
pride enhanced participants’ ability to se-
lect the best option A but had no effect on
avoiding the least fruitful option B. These
effects of amisulpride on choice behavior
were predicted by drug effects on brain
activity during both the learning and the
transfer phase. Reward prediction error
(PE)-related signals in the striatum were
enhanced by amisulpride, as was reward-
related activity in the vmPFC. While
reward-related activity in the striatum
and vmPFC showed no correlation with
performance in the transfer phase, PE-
related BOLD activity in the striatum was
predictive of later performance on win–
win trials. In the transfer phase, vmPFC
coded the expected value of each trial, i.e.,
the learned value of the two symbols on
each trial, weighted by the agent’s current
choice policy. This signal was also predic-
tive of performance on win–win-trials
and was enhanced by amisulpride. Thus,
both the enhanced coding of PE during
the learning phase and of learned value
during the transfer phase under amisul-
pride might be accountable for partici-
pants’ improved performance under this
treatment.
Our finding that vmPFC dynamically
tracks the options’ learned values dove-
tails well with a number of studies ascrib-
ing a central role to this brain area in
valuation (O’Doherty et al., 2004; Blair et
al., 2006; Plassmann et al., 2007; Hare et al., 2008; Chib et al.,
2009; Gla¨scher et al., 2009). As our study cannot dissociate pre-
cisely which component of value computation is represented
here, we do not make any specific strong claims on the exact
nature of the value computation being encoded in vmPFC.
Nonetheless, in line with others, we show that vmPFC represents
learned value, and we extend this by showing that such represen-
tations of learned value carry a dopaminergic component, as this
signal is enhanced under amisulpride. Given that blockade of
dopamine D2 receptors is well known to perturb reinforcement
learning (at least at higher doses) (Salamone, 2002), it might at
first glance appear puzzling that we find an enhancement of value
coding under amisulpride. However, it is likely that the low dose
we used led to an increase in firing of dopamine neurons and
subsequently increased dopamine release in target areas because
of a primary blockade of autoreceptors (Di Giovanni et al., 1998).
While this is a plausible explanation for the enhanced striatal PE
coding, this mechanism cannot account for the effects observed
in the vmPFC. Unlike mesostriatal dopamine neurons, mesocor-
tically projecting dopamine neurons appear to be devoid of au-
toreceptors (Kilts et al., 1987).We think that it is more likely that
amisulpride enhanced value signals in the vmPFC by shifting the
balance of D1 versus D2 receptor activation in favor of preferen-
tial D1 receptor activation. An influential account of dopaminer-
gic modulation in the PFC suggests that under preferential D2
receptor stimulation, multiple inputs may gain access to the net-
work, none ofwhich is particularly strongly represented however.
In contrast, under preferential D1 receptor stimulation, the net
Figure 6. Percentage of signal change in response to rewards and nonrewards (left) and to choose A and avoid B trials (right) in
the ventromedial prefrontal cortex during the learning and transfer phases, respectively. Signal change was extracted from
the peak coordinate of the difference between amisulpride and placebo in the respective contrast. The analysis shows that the
drug-induced difference in reward responses is primarily due to a stronger signal decrease to nonrewarding outcomes in the
amisulpride condition. The increased response in the choose A versus avoid B contrast is driven by a nonsignificant enhancement
of both the signal increase to choose A trials and the signal decrease to avoid B trials.
Figure 7. Signal change related to reward prediction errors in the striatum during the learning phase (left) and to the symbols’
learned values in the ventromedial prefrontal cortex during the transfer phase (right) correlated with correct choices on win–win
trials. White, Placebo; black, amisulpride.
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increase in inhibition causes PFC networks to be more robust
against the impact of disturbing inputs while strong inputs are
stabilized and actively maintained (Seamans and Yang, 2004).
Thus, it is plausible that amisulpride treatment enhanced value
signals by allowing representations of learned value to be stabi-
lized and shielded from the impact of disturbing noise. Our find-
ing that the enhanced response on choose A comparedwith avoid
B trials under amisulpridewas due both to an amplification of the
response to chooseA trials and a suppression of avoidB responses
lends support to an interpretation within this framework. Alter-
natively, one might argue that the effects observed in the vmPFC
may represent a remote effect that is triggered from a different
brain structure. However, we think that this is unlikely. First,
there was no area other than the vmPFC itself that showed higher
activity in the transfer phase under amisulpride. Second, amisul-
pride has a distinctive binding profile. Despite the low density of
dopamine D2 receptors in the prefrontal cortex, it has been
shown that, at low doses, amisulpride primarily occupies cortical
and limbic rather than striatal receptors (Xiberas et al., 2001;
Bressan et al., 2003).
It is noteworthy that amisulpride facilitated difficult decisions
only when choices had to be made between two highly reward-
associated symbols, but not when choosing between two very low
reward-associated symbols. Because vmPFC activity covaried
with Vstate, and Vstate is very low on lose–lose and avoid B trials,
onewould expect low value-related vmPFCactivity in these trials.
Given that the net effect of shifting the balance between prefer-
ential D1 and D2 receptor activation is an amplification of strong
inputs, it is well conceivable that the value signal elicited during
lose–lose trials is not pronounced enough to be enhanced
through this mechanism, thereby allowing only trials with a
high Vstate, i.e., win–win or choose A trials, to benefit from this
effect. It should be noted that this tentative mechanism cannot
account for the at chance-level performance on win–win trials
under placebo.
In addition to the signal in the vmPFC related to the options’
learned values, we found that activity in the posterior putamen
correlated with the learned value of the stimulus that was ulti-
mately chosen. This is consistent with the manner in which the
problem of action selection is thought to be resolved in the dorsal
striatum (Mink, 1996; Redgrave et al., 1999). Striatal circuitry is
configured such that the most salient input gains access to the
motor outputs at a winner-take-all basis, while the nonselected
responses are suppressed. This is consistent with what we find,
since signal change in the dorsal striatum positively correlated
with the learned value (i.e., “saliency”) of the chosen option. This
striatal coding of action value was also correlated with subjects’
performance. However, the striatal signal related to the value of
the chosen option was not modulated by administration of
amisulpride.
The finding that amisulpride did not affect reinforcement
learning seems at odds with a study that found that the D2 antag-
onist haloperidol attenuated reinforcement learning and striatal
prediction error coding (Pessiglione et al., 2006). This discrep-
ancy may either be caused by differences in the drugs pharmaco-
logical profiles or it may be a dose-related effect. In fact, work in
progress in our lab using a dose of amisulpride (400 mg) that
yielded plasma levels sufficient to achieve blockade of a substan-
tial proportion of striatal D2 receptors also blunted both rein-
forcement learning and striatal signals.
The observed behavioral effects of low-dose dopamine D2
receptor antagonism appear consistent with the framework sug-
gested by Frank (2005). However, our findings go beyond exist-
ing knowledge and indicate that, in addition to learning from
positive and negative outcomes, dopamine is also involved in
choice behavior on the basis of learned values, i.e., after learning
has already taken place. It may appear puzzling that amisulpride
affected choice behavior only in the transfer phase. One might
argue that the learning phase also involves choices, and these
choices should be equally affected by amisulpride. However, the
learning phase involves direct comparisons between two symbols
for which the outcome is always presented. This is clearly differ-
ent from the transfer phase, where subjects are confronted with
entirely new choice situations and where they never receive any
feedback about whether their choices were correct, i.e., where
they have no opportunity to learn from their choices.
Together, our findings show that antagonism of D2 receptors
improved performance on choices between two highly reward-
associated options and concurrently enhanced prediction error
coding in the striatum and tracking of learned value in the
vmPFC.We speculate that by blocking autoreceptors and thereby
enhancing striatal prediction error coding and by shifting the
balance of D1 versus D2 receptor activation toward preferential
D1 activation in the prefrontal cortex, amisulpride helped to sta-
bilize representations of learned value and thereby improved
choice performance.
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